within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03D_Progestogens.G03DA02_Medroxyprogesterone;

model Medroxyprogesterone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.9166666666666665e-07,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 0.02,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Medroxyprogesterone</td></tr><tr><td>ATC code:</td><td>G03DA02</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>20</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.69</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Medroxyprogesterone is a synthetic progestin, a derivative of progesterone, used primarily for hormone replacement therapy, treatment of endometriosis, dysmenorrhea, and as a component of some contraceptive formulations. It is available in both oral and injectable forms. Medroxyprogesterone acetate (MPA) is the main clinically used form. This drug is approved and in current therapeutic use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult women following a single intramuscular dose of medroxyprogesterone acetate (Depo-Provera) 150 mg.</p><h4>References</h4><ol><li><p>Zhou, XF, et al., &amp; Sang, GW (1998). Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. <i>Contraception</i> 57(6) 405–411. DOI:<a href=\"https://doi.org/10.1016/s0010-7824(98)00048-1\">10.1016/s0010-7824(98)00048-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9693401/\">https://pubmed.ncbi.nlm.nih.gov/9693401</a></p></li><li><p>Zahradnik, HP (1995). [Depot gestagens]. <i>Archives of gynecology and obstetrics</i> 257(1-4) 536–541. DOI:<a href=\"https://doi.org/10.1007/BF02264884\">10.1007/BF02264884</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8579439/\">https://pubmed.ncbi.nlm.nih.gov/8579439</a></p></li><li><p>Longo, N, et al., &amp; Sile, S (2014). Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. <i>Lancet (London, England)</i> 384(9937) 37–44. DOI:<a href=\"https://doi.org/10.1016/S0140-6736(13)61841-3\">10.1016/S0140-6736(13)61841-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24743000/\">https://pubmed.ncbi.nlm.nih.gov/24743000</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G03DA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Medroxyprogesterone;
